Introduction : Cardiovascular disease (CVD) remains a leading cause of mortality worldwide, emphasizing the need for effective prevention and management strategies
Pre-orders for the next batch are expected to open in mid-July
Prespecified subgroup, sensitivity and specificity analyses Subgroup analyses were conducted based on gender, age, body mass index (BMI), HbA1c, DM status (pre-existing or post-transplant), post-transplant eGFR, the presence of hypertension, proteinuria, heart failure, obesity, enrollment time, prior history of GLP-1RAs uses before transplant, and the concurrent use of medications, including ACEIs/ARBs, antidiabetic agents (insulin, metformin, dipeptidyl peptidase-4 inhibitors (DPP-4is), sodium-glucose cotransporter 2 inhibitors (SGLT2is), and immunosuppressants (steroids, cyclosporine and tacrolimus)
Rare allergic reactions or kidney/gallbladder issues may also occur